Two-Armed, Randomized Controlled Study of Darbepoetin Alfa (Aranesp) Plus or Minus Exercise for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies

2.50
Hdl Handle:
http://hdl.handle.net/10755/165485
Category:
Abstract
Type:
Presentation
Title:
Two-Armed, Randomized Controlled Study of Darbepoetin Alfa (Aranesp) Plus or Minus Exercise for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies
Author(s):
Tkachuk, L.; Pituskin, E.
Author Details:
L. Tkachuk, Cross Center Institute, Edmonton, Alberta, Canada; E. Pituskin
Abstract:
Anemia is a common problem for cancer patients and the oncology nurses who counsel and care for them. Anemia can be caused/exacerbated by chemotherapy, radiotherapy, infection, poor nutrition, bleeding, or bone marrow depletion. Fatigue, whether or not associated with anemia, is known to be the most frequent and debilitating symptom experienced by cancer patients. Exercise improves many of they physical, functional, and emotional sequelae of cancer and its treatments. Documented benefits of exercise include improvement in cardiovascular fitness, muscle strength, body composition, fatigue, nausea, diarrhea, anxiety, depression, and overall quality of life. No studies to date, however, have determined if these benefits from exercise apply to cancer survivors with anemia being treated with erythropoietic agents. Purpose: Therefore, we hypothesize that combination of exercise and darbepoetin alfa will have additive benefits on quality of life (QOL), fatigue, and exercise capacity among cancer patients with anemia. Theoretical/Scientific Framework: In theory, exercise and darbepoetin alfa (Aranesp) should have synergistic effects. Erythropoietin increased hemoglobin levels but it does not increase the body's ability to use hemoglobin. Conversely, while exercise can significantly improve the body's ability to use hemoglobin, its impact on hemoglobin levels is negligible. Methods: In this open-label, randomized controlled study, 100 patients with non-myeloid cancer are stratified by chemotherapy status (yes/no) and randomized to 1 of 2 treatment groups: darbepoietin alfa alone or darbepoietin alfa plus exercise. Participants randomized to darbepoetin alfa plus exercise are prescribed a supervised moderate-intensity aerobic exercise program 3 times a week for the 12-week study period. All participants receive darbepoetin alfa on weeks 1, 2, 3, 4, 5, 8, and 11. At baseline and end of study (week 13) all participants are evaluated with supervised exercise stress testing, the Godin Leisure Time Exercise Survey and FACT-Anemia Scale Questionnaire. Data Analysis: To be completed. Findings and Implications: Our primary objective is to compare improvement of QOL in mildly anemic patients (Hgb < 100 g/L) treated with darbepoetin alfa alone or darbepoetin alfa plus exercise. We will discuss available preliminary findings, in particular patient tolerance, and adherence to the prescribed exercise program.
Repository Posting Date:
27-Oct-2011
Date of Publication:
27-Oct-2011
Conference Date:
2004
Conference Name:
29th Annual Oncology Nursing Society Congress
Conference Host:
Oncology Nursing Society
Conference Location:
Anaheim, California, USA
Note:
This is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.

Full metadata record

DC FieldValue Language
dc.type.categoryAbstracten_US
dc.typePresentationen_GB
dc.titleTwo-Armed, Randomized Controlled Study of Darbepoetin Alfa (Aranesp) Plus or Minus Exercise for the Treatment of Anemia in Subjects With Non-Myeloid Malignanciesen_GB
dc.contributor.authorTkachuk, L.en_US
dc.contributor.authorPituskin, E.en_US
dc.author.detailsL. Tkachuk, Cross Center Institute, Edmonton, Alberta, Canada; E. Pituskinen_US
dc.identifier.urihttp://hdl.handle.net/10755/165485-
dc.description.abstractAnemia is a common problem for cancer patients and the oncology nurses who counsel and care for them. Anemia can be caused/exacerbated by chemotherapy, radiotherapy, infection, poor nutrition, bleeding, or bone marrow depletion. Fatigue, whether or not associated with anemia, is known to be the most frequent and debilitating symptom experienced by cancer patients. Exercise improves many of they physical, functional, and emotional sequelae of cancer and its treatments. Documented benefits of exercise include improvement in cardiovascular fitness, muscle strength, body composition, fatigue, nausea, diarrhea, anxiety, depression, and overall quality of life. No studies to date, however, have determined if these benefits from exercise apply to cancer survivors with anemia being treated with erythropoietic agents. Purpose: Therefore, we hypothesize that combination of exercise and darbepoetin alfa will have additive benefits on quality of life (QOL), fatigue, and exercise capacity among cancer patients with anemia. Theoretical/Scientific Framework: In theory, exercise and darbepoetin alfa (Aranesp) should have synergistic effects. Erythropoietin increased hemoglobin levels but it does not increase the body's ability to use hemoglobin. Conversely, while exercise can significantly improve the body's ability to use hemoglobin, its impact on hemoglobin levels is negligible. Methods: In this open-label, randomized controlled study, 100 patients with non-myeloid cancer are stratified by chemotherapy status (yes/no) and randomized to 1 of 2 treatment groups: darbepoietin alfa alone or darbepoietin alfa plus exercise. Participants randomized to darbepoetin alfa plus exercise are prescribed a supervised moderate-intensity aerobic exercise program 3 times a week for the 12-week study period. All participants receive darbepoetin alfa on weeks 1, 2, 3, 4, 5, 8, and 11. At baseline and end of study (week 13) all participants are evaluated with supervised exercise stress testing, the Godin Leisure Time Exercise Survey and FACT-Anemia Scale Questionnaire. Data Analysis: To be completed. Findings and Implications: Our primary objective is to compare improvement of QOL in mildly anemic patients (Hgb &lt; 100 g/L) treated with darbepoetin alfa alone or darbepoetin alfa plus exercise. We will discuss available preliminary findings, in particular patient tolerance, and adherence to the prescribed exercise program.en_GB
dc.date.available2011-10-27T12:19:23Z-
dc.date.issued2011-10-27en_GB
dc.date.accessioned2011-10-27T12:19:23Z-
dc.conference.date2004en_US
dc.conference.name29th Annual Oncology Nursing Society Congressen_US
dc.conference.hostOncology Nursing Societyen_US
dc.conference.locationAnaheim, California, USAen_US
dc.description.noteThis is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.-
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.